Nektar Therapeutics reported $952.9 million in cash and investments as of September 30, 2026. Its cash runway is expected into the third quarter of 2028, past Phase 3 ZENITH AD readouts in atopic dermatitis in the summer of 2028.
NKTR · Nektar Therapeutics
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Nektar Therapeutics initiated three Phase 3 ZENITH AD trials, plans ZENITH AA-1 for December 2026, and reported $952.9 million in cash and marketable securities at September 30, 2026.
RESPEG entered global Phase 3 studies for atopic dermatitis, with the alopecia areata study planned for December and data expected in summer 2028. The company ended Q3 2026 with $953 million in cash and investments and no debt.
Nektar Therapeutics reported that rezpegaldesleukin entered Phase 3 development, while cash and investments in marketable securities reached $952.9 million on September 30, 2026; third-quarter revenue was $9.4 million and net loss was $55.7 million.
Nectar reported that ResPeg maintained SALT20 responses in 63% of responders six months after treatment; the planned Phase III will advance 24 micrograms per kilogram every two weeks for 52 weeks, enrolling approximately 850 patients in early 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 12, 2026TL;DR. Nektar advanced rezpegaldesleukin into all three Phase 3 atopic dermatitis trials, moved the alopecia areata trial forward, reported positive Phase 2 results and ended the quarter with approximately $953 million of cash and investments and no debt. Revenue declined while operating expenses and net loss increased as Phase 3 development advanced, and clinical development retains a high risk of failure with no assurance of regulatory approval.
- + All three global ZENITH AD registrational trials have been initiated.
- + The global ZENITH AA registrational trial is on track to start in December, earlier than previously planned.
- + The Phase 2b REZOLVE-AD study met all primary and key secondary endpoints on the 24 micrograms per kilogram every-two-week regimen.
- + Alopecia areata responses were maintained after treatment discontinuation, and hair regrowth continued to improve during six months off treatment.
- + Nektar ended the third quarter with approximately $953 million in cash and investments and no debt.
- + Nektar plans a proof-of-concept study of rezpegaldesleukin in approximately 30 patients with vitiligo.
- − Third-quarter revenue declined to $9.4 million from $11.8 million in the prior-year quarter.
- − Third-quarter operating costs and expenses increased to $67.2 million from $43.5 million in the prior-year quarter.
- − Third-quarter R&D expense increased to $44.1 million from $27.3 million in the prior-year quarter.
- − The company expects fourth-quarter R&D expense to increase because of clinical enrollment, startup and CMC activities.
- − Third-quarter net loss increased to $55.7 million from $35.5 million in the prior-year quarter.
- − Clinical development remains subject to a high risk of failure and no assurance of regulatory approval.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Research
our published analysis of this companyEquibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash and investments in marketable securities | $952.9M | September 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NKTR
this stock
Nektar Therapeutics
|
$1.23B | -15.1% | +86.0% | — | 19.8% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$135.44B | +17.8% | +46.2% | 34.4 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$99.08B | +24.1% | +20.8% | 21.2 | 2.1% |
|
MRNA
Moderna, Inc.
|
$83.68B | +601.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$64.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 13, 2026
- This year
- 27
Nektar Therapeutics reported $952.9 million in cash and investments as of September 30, 2026. Its cash runway is expected into the third quarter of 2028, past Phase 3 ZENITH AD readouts in atopic dermatitis in the summer of 2028.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NKTR | -5.0% | -8.4% | -44.8% | -7.6% | -15.1% |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | -2.6% | -3.7% | -41.8% | -4.5% | -22.5% |